Test Phase IV, Multicenter, Open, Aiming to test the difference in efficacy of Natalizumab, Versus Fingolimod the 2 drugs Having A AMM for Treatment of Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms BEST-MS
- 30 Oct 2019 This trial has been completed in France, according to European Clinical Trials Database. (2019-01-23)
- 27 Apr 2018 Results (n=224) assessing efficacy and tolerability of natalizumab with fingolimod as second-line treatment in patients with multiple sclerosis, were presented at the 70th Annual Meeting of the American Academy of Neurology.
- 21 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Nov 2017.